Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Biotechnology company Ococyte Corporation (NYSE AMERICAN: OXC) shares are rallying premarket on Tuesday after it was announced that the company has entered into an exclusive licensing agreement with China-based Burning Rock Biotech (NASDAQ: BNR).
The deal will see the two companies bring DetermaRx, a treatment stratification test for early-stage lung cancer patients, to China.
“We believe aligning with one of the largest and fastest-growing companies in China’s NGS-based cancer therapy selection market speaks to the strength of DetermaRx as a valuable treatment stratification tool to help clarify this critical treatment decision point in early-stage tumors,” commented Ron Andrews, President and CEO of Oncocyte.
Oncocyte will speed up the ongoing expansion of DetermaRx tests to patients and physicians outside of the US as part of the collaboration.
Shares of Oncocyte are currently trading at $3.28, up 54.72% from the previous day’s close at $2.12.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .